Answers are grounded in this paper and cite their sources.
Isolated obscurolide A2 demonstrates cytotoxicity in prostate cancer cells, suggesting its potential as an anticancer agent.
We isolated and characterised seven obscurolides: obscurolide A2 (1), B2α (2), B2β(3), A1 (4), streptalbonin G (5), streptalbonin F (6), and (3 R)-obscurolide A (7), from Streptomyces chartreusis SA-7, a soil actinomycete from the Northwestern Himalayas, India. Preliminary screening revealed that obscurolide A2 (1) exhibited better cytotoxicity against prostate cancer (PC-3) cells (IC50: 12.16 ± 2.12 μM). Mechanistic studies confirmed that A2 (1) significantly inhibits PC-3 cells’ clonogenic formation and induces mitochondrial-mediated apoptosis via modulation of Bax/Bcl-2 and caspase 3 expression. Structure-activity relationship (SAR) analysis identified the C-4′ aldehydic substituent and the intact γ-butyrolactone core (GBL) as key pharmacophores for cytotoxicity. This study provides the first mechanistic evidence of the anticancer potential of obscurolides, highlighting A2 (1) as a promising GBL scaffold for further preclinical investigation.
No takes yet. Share an insight, caveat, or question.
Rana et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: